Acute and chronic systemic corticosteroid-related complications in patients with severe asthma

Journal of Allergy and Clinical Immunology

Volumn 136, Issue 6, 2015, Pages 1488-1495

  Lefebvre, Patrick ^a   Duh, Mei Sheng ^b   Lafeuille, Marie Hélène ^a   Gozalo, Laurence ^a   Desai, Urvi ^b   Robitaille, Marie Noëlle ^a   Albers, Frank ^c   Yancey, Steve ^c   Ortega, Hector ^c   Forshag, Mark ^c   Lin, Xiwu ^c   Dalal, Anand A ^c  

^a GROUPE D ANALYSE   (Canada)

^b ANALYSIS GROUP   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

corticosteroid related complications; cost; dose response; health care use; severe asthma; Systemic corticosteroids

Indexed keywords

CORTICOSTEROID; ANTIASTHMATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BONE DISEASE; CARDIOVASCULAR DISEASE; CHILD; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EXPOSURE; EMERGENCY WARD; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL DISEASE; METABOLIC DISORDER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SYSTEMIC THERAPY; DOSE RESPONSE; ECONOMICS; MIDDLE AGED; PATIENT ATTITUDE; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; YOUNG ADULT;

EID: 84952639251     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.07.046     Document Type: Article

References (30)

1. National Heart, Lung, and Blood Institute Guidelines for the diagnosis and management of asthma 2007 National Heart, Lung, and Blood Institute Bethesda (MD)
2. E.H. Bel, S.E. Wenzel, P.J. Thompson, C.M. Prazma, O.N. Keene, S.W. Yancey, and et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma N Engl J Med 371 2014 1189 1197
3. S. Pakhale, S. Mulpuru, and M. Boyd Optimal management of severe/refractory asthma Clin Med Insights Circ Respir Pulm Med 5 2011 37 47
4. G.J. Rodrigo, C. Rodrigo, and J.B. Hall Acute asthma in adults: a review Chest 125 2004 1081 1102
5. J.I. Ivanova, R. Bergman, H.G. Birnbaum, G.L. Colice, R.A. Silverman, and K. McLaurin Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma J Allergy Clin Immunol 129 2012 1229 1235
6. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma Eur Respir J 22 2003 470 477
7. L.G. Heaney, C.E. Brightling, A. Menzies-Gow, M. Stevenson, and R.M. Niven Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry Thorax 65 2010 787 794
8. E. Sarnes, L. Crofford, M. Watson, G. Dennis, H. Kan, and D. Bass Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review Clin Ther 33 2011 1413 1432
9. A. Elixhauser, P. Owens for the Agency of Healthcare Research and Quality Adverse drug events in U.S. hospitals, 2004 Healthcare Cost and Utilization Project. Statistical Brief #29. 2007 1 12
10. J.N. Hoes, J.W. Jacobs, S.M. Verstappen, J.W. Bijlsma, and G.J. Van der Heijden Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis Ann Rheum Dis 68 2009 1833 1838
11. M. Thamer, M.A. Hernán, Y. Zhang, D. Cotter, and M. Petri Relationship between prednisone, lupus activity and permanent organ damage J Rheumatol 36 2009 560 564
12. Bureau of Labor Statistics. Consumer Price Index (CPI). 2014. Available at: http://www.bls.gov/cpi/. Accessed February 8, 2015.
13. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383
14. W. Pan Akaike's information criterion in generalized estimating equations Biometrics 57 2001 120 125
15. J.A. Da Silva, J.W. Jacobs, J.R. Kirwan, M. Boers, K.G. Saag, L.B. Inês, and et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data Ann Rheum Dis 65 2006 285 293
16. T.P. Van Staa, H.G. Leufkens, and C. Cooper The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis Osteoporos Int 13 2002 777 787
17. J.R. Curtis, A.O. Westfall, J. Allison, J.W. Bijlsma, A. Freeman, V. George, and et al. Population-based assessment of adverse events associated with long-term glucocorticoid use Arthritis Rheum 55 2006 420 426
18. S.C. Manson, R.E. Brown, A. Cerulli, and C.F. Vidaurre The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use Respir Med 103 2009 975 994
19. F. Richy, J. Bousquet, G.E. Ehrlich, P.J. Meunier, E. Israel, H. Morii, and et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review Osteoporos Int 14 2003 179 190
20. F. De Vries, M. Bracke, H.G. Leufkens, J.W. Lammers, C. Cooper, and T.P. Van Staa Fracture risk with intermittent high-dose oral glucocorticoid therapy Arthritis Rheum 56 2007 208 214
21. M. Steinbuch, T.E. Youket, and S. Cohen Oral glucocorticoid use is associated with an increased risk of fracture Osteoporos Int 15 2004 323 328
22. A. Zonana-Nacach, S.G. Barr, L.S. Magder, and M. Petri Damage in systemic lupus erythematosus and its association with corticosteroids Arthritis Rheum 43 2000 1801 1808
23. L.J. Walsh, C.A. Wong, J. Oborne, S. Cooper, S.A. Lewis, M. Pringle, and et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease Thorax 56 2001 279 284
24. I. Karp, M. Abrahamowicz, P.R. Fortin, L. Pilote, C. Neville, C.A. Pineau, and et al. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum 59 2008 169 175
25. C. Varas-Lorenzo, L.A. Rodriguez, A. Maguire, J. Castellsague, and S. Perez-Gutthann Use of oral corticosteroids and the risk of acute myocardial infarction Atherosclerosis 192 2007 376 383
26. P.C. Souverein, A. Berard, T.P. Van Staa, C. Cooper, A.C. Egberts, H.G. Leufkens, and et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study Heart 90 2004 859 865
27. S. O'Neill, J. Sweeney, C.C. Patterson, A. Menzies-Gow, R. Niven, A.H. Mansur, and et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry Thorax 70 2015 376 378
28. D.A. Stempel, C.S. Roberts, and R.H. Stanford Treatment patterns in the months prior to and after asthma-related emergency department visit∗ Chest 126 2004 75 80
29. U.S. Food and Drug Administration. FDA approves the first non-hormonal treatment for hot flashes associated with menopause. FDA News Release. 2013. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm359030.htm. Accessed August 27, 2015.
30. Global Initiative for Asthma. Global strategy for asthma management and prevention. Global Initiative for Asthma; 2014. Available at: http://www.ginasthma.org/documents/4. Accessed January 9, 2015.